Kornimate/medical-research-clean huggingface dataset:
a study of the efficacy of atorvastatin in lowering cholesterol in latin american patients with high cholesterol

Conditions: Dyslipidemias

Summary: the purpose of this study is to determine the percentage of patients who would reach a cholesterol goal after atorvastatin treatment.


Eligibility criteria:
inclusion criteria: * patients with high cholesterol eligible for treatment with baseline ldl-c level of less than or equal to 220 mg/dl * willingness to follow diet exclusion criteria: * triglycerides less than or equal to 400 mg/dl * hemoglobin a1c \>10%
focal brachytherapy in patients with selected "low-risk" prostate cancer - a phase-ii-trial

Conditions: Prostate Cancer

Summary: this trial examines the feasibility and toxicity of focal brachytherapy in patients with low-risk prostate cancer.

patients with low-risk prostate cancer will receive hdr-brachytherapy: 2 x 13,5 gy.

Eligibility criteria:
inclusion criteria: * age \> 18 * histologically confirmed prostate cancer * gleason score of index lesion ≤ 6 (3+3) * tumor stage: ct1-2a cn0 cm0 * unilateral affection; index lesion ≤ 0.5ml with or without clinically non-significant lesion contralateral. no more than 25% of the punch should be affected. therefore a 3d-tpm-biopsy is mandatory before treatment. * psa ≤ 10/ng/ml * prostate volume \< 60 m\^3 * no distant metastasis * life expectancy \> 10 years * informed consent exclusion criteria: * tumor stage ≥ t2b * known metastasis: n+ and/or m1 * general anesthesia or peridural anesthesia is not possible * coagulation disorder

Keywords: prostate cancer focal brachytherapy psa biological marker
dose-ranging study

Conditions: Abdominal Contour Defects

Summary: dose ranging study


Eligibility criteria:
inclusion criteria: * 18 - 45 years of age inclusive * abdominal contour defect * bmi \<25 kg/msq * stable diet and exercise and body weight exclusion criteria: * prior treatment of abdominal contour defects (liposuction, abdominoplasty, etc) * known hypersensitivity to study drugs

Keywords: adiposity
montessori-based activities for elderly persons with dementia

Conditions: Dementia

Summary: this study will determine whether montessori-based activities can help older adults with dementia become more responsive to others.

studies have shown that montessori-based activities, which focus on developing an individual's unique abilities, are effective in increasing engagement between nursing home residents with dementia and their caregivers. this study will determine whether the positive effects of montessori-based programming can be replicated in adult day care, assisted living, and nursing homes. results from this study will be used to create training materials to help staff in different settings implement the intervention within existing schedules, staffing, and programming routines. this study will be conducted in two phases. during phase i, participants with mild dementia will be trained to become small group leaders for montessori-based activities. in phase ii, newly-trained participants will use their skills to assist others. assessments will be made throughout the study. participants' engagement with the environment and caregiver burden and satisfaction will be assessed.

Eligibility criteria:
inclusion criteria: * diagnosis of dementia * living in or attending programs at participating sites exclusion criteria: * medical conditions that would interfere with study participation

Keywords: aged nursing homes assisted living facilities
reproducibility study of over active bladder symptom score [oabss]

Conditions: Overactive Bladder

Summary: the purpose of this study is to evaluate the reproducibility of over active bladder symptom score (oabss) in asian countries.


Eligibility criteria:
inclusion criteria: * symptoms oab for 3 months or longer * at least 1 urgency episode in last 3 days * symptoms of oab as verified by the screening 3-day bladder diary, defined by: * number of micturition ≥8 times/day * number of urgency episode in 3 days ≥1 exclusion criteria: * indwelling catheters or practicing intermittent self-catheterization * symptomatic urinary tract infection, chronic inflammation * diabetic neuropathy

Keywords: oabss
markers of infection and resistance in invasive fusariosis

Conditions: Fusariosis

Summary: in recent decades, invasive fusarioses have been emerging fungal pathologies with high mortality. the prognosis depends on the speed of the diagnosis, but currently biological diagnosis is mainly based on fungal culture, no specific biomarker for this microorganism is available in current clinical practice. the genus fusarium also shows reduced sensitivity to antifungals commonly used and recommended in clinical practice, such as voriconazole or amphotericin b. the main objective of this study is to describe the proportions of different fungal species in positive fungal cultures in patients with invasive fungal infection (ifi) or fungal keratitis. the secondary objectives are the description of the dosage of galactomannans, beta (1,3) -d-glucans and the rate of detection of dna circulating in case / control groups for the 2 clinical forms studied. in patients with evidence of fusarium wilt, the study will describe the distribution of the different minimum inhibitory concentrations (mic) depending on whether or not different antifungals are taken, the vital status at 3 months, and the response or not to treatment. finally, the presence of genetic markers will be described according to the groups of mic values.


Eligibility criteria:
inclusion criteria: * suspicion of invasive fungal infection involving the performance of a blood culture or a skin biopsy or diagnosis of keratitis involving the taking of a cornea sample * fungal culture carried out on this sample * person having been informed of the research and not having opposed the use of their data exclusion criteria: * clinical diagnosis of superficial fusarium wilt (onychomycosis, etc.)
preliminary research on two-step dosing of imipenem/cilastatin

Conditions: Sepsis

Summary: explore imipenem/cilastatin two-step dosing compared to 2 hours infusion in patients with severe whether can obtain better results of the pharmacokinetic/pharmacodynamic, for clinical rational use of antimicrobial agents, and provide theoretical support for optimizing dosage regimen.

compared with imipenem/cilastatin 2 hours continuous dosing method and two-step dosing method (0.5 hours before enter half dose, after 1.5 hours, the other half of the input dose) of blood drug concentration in the body than the minimal inhibitory concentrations (mic) pathogens percent of dosing interval duration (100% ft \> mic), blood drug concentration in the body more than 4 times the minimal inhibitory concentrations (mic) pathogens percent of dosing interval duration (100% ft \> 4 mic), blood drug concentration peak and the ratio of the minimal inhibitory concentrations (mic) pathogens (cmax/mic), blood drug concentration (tmax) used in the peak time, used to guide clinical patients with severe infection of imipenem/cilastatin usage.

Eligibility criteria:
inclusion criteria: * sepsis or severe sepsis or severe infections in the previous 48 hours * treatment with imipenem/cilastatin (recommended by hospital microbiologists) * expected duration of hospital stays in the icu ≥ 72 h from recruitment * recruited patients agreed to participate in this trial, and had set up a signed informed consent exclusion criteria: * with an allergy to carbapenems or with an adverse drug reaction to imipenem * acute or chronic renal failure assessed by serum creatinine concentrations \> 280 μmol/l (or creatinine clearance \<20ml/min) or those requiring continuous renal replacement therapy * drug or alcohol abuse * pregnant and lactant women * patients near to death

Keywords: pharmacokinetics; pharmacodynamic; imipenem; sepsis
convalescent plasma for covid-19 patients

Conditions: COVID 19

Summary: the investigators propose to evaluate intravenous administration of convalescent plasma (cp) obtained from covid19 survivors in covid19 patients who are in the medium stage. supportive data exist for use of convalescent plasma in the treatment of covid19 and other overwhelming viral illnesses. the study team wants to test the hypothesis that treatment with covid19 cp will demonstrate salutary effects on covid19 disease severity/duration, with the primary objective to reduce mortality. in addition, a major secondary objective to reduce the requirement for and/or duration of mechanical ventilation. the first phase is to test the safety of cp therapy.

coronaviruses are among the most common causes of the common cold in humans.1,2 in recent decades, coronavirus has caused several epidemic worldwide with a vast number of deaths such as severe acute respiratory syndrome-sars (2003) with 8098 people infected and 774 people died over 29 countries. the disease caused by sars cov-2 (covid19) is manifest by fever, fatigue, dry cough, pharyngitis, and headache. in addition to the common clinical presentation of respiratory distress, and increasing frequency of cardiovascular manifestations has become evident. in this context, the investigators propose to evaluate the safety of intravenous administration of convalescent plasma (cp) obtained from covid19 survivors in patients requiring hospitalization for symptomatic "high risk" covid19 disease. the study team wants to test the hypothesis that treatment with covid19 cp will demonstrate salutary effects on covid19 disease severity/duration, with the primary objective to reduce mortality. in addition, a major secondary objective to reduce the requirement for and/or duration of mechanical ventilation this is a single-arm, non-randomized, open-label treatment of eligible subjects defined as those who satisfy all inclusion criteria. written informed consent will be obtained all eligible subjects prior to participation. convalescent plasma will be obtained from male donors, nulliparous females, or female donors negative for hla antibodies at least 14 days following recovery from covid-19 infection.

Eligibility criteria:
inclusion criteria: * age 18-75 years * sars-cov-19 pcr positive * medium stage * time from onset to screening ≤ 21 days, the sars-cov-2 test is still positive exclusion criteria: * patients with a history of autoimmune disease or iga deficiency * patients with a history of allergy * multi-organ/system failure * pregnant or breastfeeding at the time of study * cancer, history of heart failure, stroke, bronchial asthma * multi-organ/system failure with indications for dialysis, severe hypoxia, failure with conventional treatment methods, indications for ecmo. * the patient is infected with multidrug-resistant bacteria. * the patient is participating in another study. * time from onset to screening\> 21 days
an exploratory study to assess the efficacy of the avène hydrotherapy

Conditions: Chronic Pruritus Due to Plaque Psoriasis

Summary: to assess the benefit of the avène hydrotherapy in subjects with pruritic plaque psoriasis

* to assess the benefit of the avène hydrotherapy in subjects with pruritic plaque psoriasis in the: * improvement of pruritus * improvement of psoriasis severity * improvement of quality of life * change of pruritus and psoriasis biological markers * intake/application of treatments and skin care products for psoriasis and pruritus management, evaluated during a follow-up period * to assess the time to pruritus relapse evaluated in subjects with pruritic plaque psoriasis, during the period following the avène hydrotherapy (for the hydrotherapy group only) * to assess the global efficacy of the avène hydrotherapy in pruritic plaque psoriasis, according to subjects' and investigators' opinion (for the hydrotherapy group only) * to assess the global cutaneous tolerance of the avène hydrotherapy in subjects with pruritic plaque psoriasis (for the hydrotherapy group only)

Eligibility criteria:
inclusion criteria: * subject with plaque psoriasis * subject with moderate to very severe chronic pruritus whose nrs score ≥ 4, (on a scale ranged from 0 to 10) * subject with chronic pruritus, i.e. for at least 6 weeks, due to plaque psoriasis exclusion criteria: * subject with erythrodermic psoriasis, pustular psoriasis or palmoplantar keratoderma * subject with any other type of pruritus, not related to plaque psoriasis * subject with an acute, chronic or progressive disease other than plaque psoriasis which could be the origin of the pruritus * biotherapy, phototherapy or puvatherapy treatment * psoriasis treatment by laser * systemic or topical treatment taken/applied for psoriasis or pruritus management established or modified since the selection visit or planned to be established or modified between the inclusion visit and the end of the hydrotherapy
investigating the preventative ability of massage therapy on paclitaxel induced peripheral neuropathy

Conditions: Breast Cancer; Neuropathy; Neuropathy;Peripheral

Summary: feasibility study to examine the preventative ability of massage therapy on paclitaxel induced peripheral neuropathy in breast cancer


Eligibility criteria:
inclusion criteria: 1) breast cancer diagnosis 2) planning to receive chemotherapy treatment with paclitaxel in the curative setting (adjuvant or neoadjuvant) on a weekly or bi-weekly schedule exclusion criteria: 1)diabetes or other neurological disorder 2) current or previous peripheral neuropathy 3)previous treatment with paclitaxel 4)active deep vein thrombosis (dvt) within last 12 months or history of untreated lower extremity dvt

Keywords: massage breast cancer neuropathy
low grade serous ovarian carcinoma and uterine involvement : should hysterectomy be the rule

Conditions: Serous Ovarian Carcinoma; Low Grade Serous Ovarian Carcinoma

Summary: investigators studied a population of 28 low grade serous ovarian carcinoma treated in hospices civils de lyon between 2000 and 2022. the primary objective is to determinate the rate of myometrial involvement by the cancer at pathology examination. then, investigators compared patients with or without myometrial involvement : survival parameters, predictive factors of myometrial involvement (age, ca 125 level, surgery characteristics, pathology characteristics).


Eligibility criteria:
* inclusion criteria : * 18 years old or more * low grade serous ovarian cancer (mdacc classification) * grade 1 serous ovarian carcinoma (silverberg classification) * exclusion criteria : * no sufficient data available * grade 2 and 3 serous ovarian carcinoma

Keywords: serous ovarian carcinoma low grade serous ovarian carcinoma fertility sparring surgery hysterectomy
a randomized, double-blind, placebo controlled phase iii study to investigate efficacy and safety of first-line treatment with hlx10 + chemotherapy (carboplatin-nanoparticle albumin bound (nab) paclitaxel) in patients with stage iiib/iiic or iv nsclc

Conditions: Squamous Non Small Cell Lung Cancer

Summary: this study is a randomized, double-blind, multicenter, phase iii clinical study to compare the clinical efficacy and safety of hlx10 + chemotherapy vs chemotherapy in subjects with locally advanced or metastatic squamous nsclc who have not previously received systemic treatment. eligible subjects in this study will be randomized to arm a or arm b at 2:1 ratio as follows: arm a (hlx10 arm): hlx10 + chemotherapy (carboplatin nab paclitaxel) arm b (placebo arm): placebo + chemotherapy (carboplatin nab paclitaxel) the three stratification factors for randomization include: pd-l1 expression level (tumor proportion scores \[tps\]≥50%, 50%\>tps≥1%, tps\<1%), asian population (yes or no), nsclc stage (stage iiib/iiic or stage iv), and carboplatin auc (5 or 6).


Eligibility criteria:
inclusion criteria: 1. patients with histologically or cytologically confirmed stage iiib/iiic and stage iv (ajcc edition 8) squamous nsclc where surgery or radiotherapy cannot be performed. 2. no known sensitizing egfr mutations or alk, ros1 gene rearrangements. 3. major organs are functioning well 4. participant must keep contraception 5. patients with prior denosumab use who can agree to switch to bisphosphonate therapy for bone metastases in the study. exclusion criteria: 1. patients with histologically non-squamous nsclc. mixed tumors will be classified according to the primary cell type. patients do not meet the requirements for enrollment if small cell components and neuroendocrine carcinoma components are present. for non-small cell histology, patients meet the requirements for enrollment if squamous components (e.g., adenosquamous) are present. 2. patients with known history of severe hypersensitivity to any monoclonal antibody. 3. patients with known hypersensitivity to any compositions of carboplatin or nab-paclitaxel. 4. pregnant or breastfeeding females. 5. patients with a known history of psychotropic drug abuse or drug addiction; or a history of alcohol abuse. 6. patients who have other factors that could lead to the early termination of this study based on the investigator's judgment.

Keywords: locally advanced or metastatic squamous non small cell lung cancer
molecular mechanisms of senescence predisposing to cancer : exploratory analysis on healthy tissues (skinage).

Conditions: Sarcoma

Summary: epidemiological data show that the incidence of carcinoma, the most common cancer, is strongly linked to the age. non melanoma skin carcinomas (nmscs) (the most frequent cancers in the elderly population) derive from keratinocytes of the basal layer of the epidermis, from differentiated keratinocytes of the more superficial layers or from stem cells of hair follicles. unlike nmscs, soft-tissue sarcomas, including those deriving from dermal fibroblasts, are very rare (less than 1% of all cancers). our overall purpose is to decipher the molecular pathways activated during the aging of these tissues that may explain why they have a so different propensity to undergo a malignant transformation. given that senescent cells accumulate in the dermis and epidermis with age, we will constitute two groups : "young skin" that we arbitrarily limit to the range ≥ 18 and ≤ 40 and "aged skin" ≥ 55. thus the main objective of our study is to search within 2 age groups (≥ 18 and ≤ 40 years and ≥ 55 years) the expression of senescence markers on healthy skin tissue.

* information and obtaining informed consent. * collection of clinical data. * collection of two samples of healthy skin tissue, without disfigurement, during an intervention under general anesthesia for the treatment of a sarcoma. * freezing samples of healthy skin tissue in liquid nitrogen within 10 minutes after collection. * transfer of the samples to the laboratory of anatomopathology. * preparation of the healthy skin samples by the laboratory of anatomopathology. * transfer of the conditioned samples to the institut de biologie de lille for analysis. * control of the aesthetic appearance during the postoperative consultation. * destruction of the samples at the end of analysis.

Eligibility criteria:
inclusion criteria: * patient with an operable sarcoma * requiring a surgical operation under general anesthesia at the oscar lambret centre * age ≥ 18 ans, belonging to one of the two following age groups : \[ ≥ 18 and ≤ 40 years\] and \[ ≥ 55 years\] * patient having a social security scheme * patient having signed an informed consent form for the study exclusion criteria: * patient aged under 18 or between 41 and 54 * location of the tumor on the face, neck or neckline * patient with a skin tumor * tumor-induced cutaneous fistula making suspect a tumor invasion of the skin * patient with a chronic skin disease * collection in an area already treated by surgery, radiotherapy or brachytherapy * pregnant or breastfeeding women * patient under guardianship or tutorship

Keywords: mechanisms of senescence senescence markers
relapse prevention with varenicline

Conditions: Recurrence; Smoking Cessation; Substance-Related Disorders

Summary: this study aims to determine if varenicline (chantix®), currently used as a smoking cessation aid, will decrease the likelihood of relapse to smoking following a programmed lapse in the laboratory. the hypothesis is that varenicline will reduce the reinforcing effects of smoking and will delay or prevent relapse compared to placebo.

in this study, the investigators plan to use an experimental model of a lapse, in which volunteers smoke two cigarettes after a brief period of (12-24 hours). the goals of this study are to assess the impact of varenicline on the subjective and reinforcing effects of cigarettes, as well as the latency to resume smoking (relapse) following the lapse exposure.

Eligibility criteria:
inclusion criteria: * age 18-75 years old * reports smoking at least 10 cigarettes per day and provides a urine sample that tests positive for nicotine metabolites at intake * contemplating a smoking cessation attempt in the near future * willing to engage in a practice quit attempt during which they will be asked to smoke on one occasion * able to give informed consent exclusion criteria: * currently meets diagnostic and statistical manual (dsm-iv) criteria for depression, bi-polar disorder, or schizophrenia * history of attempted suicide or expresses any current suicidal ideation * pregnant, breast feeding, or planning to become pregnant within the next 3 months * reports desire for immediate treatment of tobacco/nicotine dependence * severe impairment of renal function indicated by glomerular filtration rate (gfr) less than 30 ml/min calculated using the cockcroft and gault prediction method (plasma creatinine adjusted by weight, gender, and age)

Keywords: relapse smoking cessation substance abuse